Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Data ReadoutpositiveDCVax-LPositive

AI Analysis

Summary

Northwest Biotherapeutics presented updated Phase III trial data for DCVax-L in glioblastoma showing improved survival extension based on individual patient level data analyses. The company indicates the original survival benefit analysis was likely underestimated in the independent reanalysis.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Updated survival data from Phase III trial presented showing original analysis of survival extension was likely underestimated

Importance:7/10

Sentiment:

0.70

phase_3_dataglioblastomasurvival_dataimmunotherapyclinical_trial

Related Companies

$NWBO

Read the original article

Published by PR Newswire Biotech on July 8, 2026 6:24 PM

Read Original